Annexon, Inc.

Brisbane, CA

UEI
KVPFLBUEA8C7
CAGE
6K3S3
Primary NAICS
541714 Research and Development in Biotechnology (except Nanobiotechnology)
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • For Profit Organization
Entity structure
Corporate Entity (Not Tax Exempt)
SAM.gov registration date
Physical address
1400 Sierra Point Pkwy #200, Brisbane, CA 94005, USA
Website
annexonbio.com
Founded
2011
Employees
51-250
Estimated annual revenue
$10M-$50M
Industry
  1. Health Care
  2. Pharmaceuticals, Biotechnology & Life Sciences
  3. Pharmaceuticals
SIC code
28 Chemical & Allied Products
Profiles

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Grant awards

Award Agency Obligated Awarded
The effect of ANX005, an anti-C1Q antibody, on biomarkers of target and pathway engagement and neurodegeneration in ALS… W81XWH2110398 Defense Health Agency $143,840
Development of novel inhibitors of C1Q for the treatment of neurodegenerative diseases R44AG054404 National Institutes of Health $1,213,915
Development of novel inhibitors of complement for the treatment of alzheimer's DI R43AG043302 National Institutes of Health $167,000

Quick answers

Is Annexon, Inc. registered in SAM.gov?

Yes. Annexon, Inc.'s SAM.gov registration is active through June 8, 2027.

What is Annexon, Inc.'s most recent federal award?

Annexon, Inc.'s most recent federal grant award is The effect of ANX005, an anti-C1Q antibody, on biomarkers of target and pathway engagement and neurodegeneration in ALS… (W81XWH2110398), from Defense Health Agency, on June 1, 2021.

On GovTribe

See Annexon, Inc.'s full federal record

  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login